SAMe 400 mg

SAMe 400 mg

Protocol For Life Balance4.9 (52 ratings)
Format:Tablet Quantity: 60 Tablet(s) · 30 servings
Goals
$75.00 $2.50 per serving
iHerbLowest$75.00Pure Formulas$75.00Vitacost$75.00

About this product

The serving provides a full-strength SAMe amount for mood, joint, stress, and methylation-related use. Its single-active design is focused.

No stable salt or enteric coating is stated, and the label does not clarify net SAMe. Storage protection is also not described.

The product is expensive relative to better-documented alternatives. A protected, stabilized tablet offers a safer purchasing decision.

Who is it for
  • Adults who specifically prefer this tablet
  • Users already familiar with full-dose SAMe
  • People accepting limited delivery detail
Best for
  • Full-strength SAMe dosing
  • Simple single-active use
  • Multi-goal SAMe routines

Pros

  • Full commonly used amount
  • Single active ingredient
  • Exact serving weight listed
  • Focused formula

Cons

  • Salt form is unspecified
  • No enteric protection
  • No moisture-protective packaging identified
  • High cost

Warnings

  • SAMe may trigger mania in people with bipolar disorder
  • Do not combine with serotonergic antidepressants, MAO inhibitors, or triptans without professional oversight
  • SAMe may cause insomnia, anxiety, nausea, or diarrhea

Product analysis

69 out of 100
Full-strength dosing is outweighed by poor form and delivery disclosure plus high cost.

AI assessment of the formula, label and price. How scoring works

Nutrient quality84

Neither a stabilized salt nor acid-resistant delivery is identified. A full commonly used amount provides strong active depth, although net SAMe yield remains unclear.

Ingredient transparency79

The active amount is disclosed without a hidden blend. Missing net active yield, complete directions, and non-active ingredients leave important gaps.

Customer satisfaction66

The supplied average rating is very strong and the rating volume is moderate. No specific experience details were provided to judge repeated complaints or purpose alignment.

Value for money42

Delivery limitations or high cost weaken practical value. Better-protected or more efficiently priced alternatives are more competitive.

Format
Tablet
Container
60 Tablet(s)
Per serving
$2.50
Customer rating
4.9 · 52 ratings
Report analysis

Goals

Mood Support
Mood Support
Impact
Moderate effect
B- Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe may help with depressive symptoms in some treatment contexts, particularly alongside an antidepressant, but its benefit on its own is less clear. That doesn't imply that generally healthy adults will feel a mood improvement. The serving supplies 400 mg, below the 800–1600 mg daily amounts associated with those treatment contexts; one serving also doesn't tell you the daily exposure.

How this product is rated for Mood Support

Ingredient fit75

SAMe has a connection to this goal, with limits on how directly that translates into everyday mood improvement.
Goal fit
SAMe has a connection to this goal, with limits on how directly that translates into everyday mood improvement..
Dose adequacy
SAMe 400 mg per serving; these amounts describe exposure, not a guarantee of mood benefit.

Pathways11

A connection to chemical signalling or stress responses is different from a demonstrated improvement in how you feel.
Depth
A connection to chemical signalling or stress responses is different from a demonstrated improvement in how you feel.
Breadth
Several biological connections do not by themselves demonstrate several distinct emotional benefits.

Evidence67

Effects depend on the ingredient and preparation; possible mood-related effects do not guarantee a noticeable everyday benefit.
Evidence strength
Effects depend on the ingredient and preparation; possible mood-related effects do not guarantee a noticeable everyday benefit.
Studied preparation
The declared ingredients retain their preparation-specific limits; matching an ingredient name does not guarantee the same personal response.

Formulation logic100

No particular ingredient conflict or missing required partner is identified. Combining ingredients does not by itself demonstrate an added mood benefit.
Partner coverage
No additional partner ingredient is required by the available ingredient-specific information.
Conflicts
No particular conflict between the declared ingredients is identified.
Effective doses
SAMe 400 mg per serving; these amounts describe exposure, not a guarantee of mood benefit.
Study evidence
SAMe Disputed 20 studies
Joint Health
Joint Health
Impact
High effect
B- Ingredient FitF PathwaysB+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe may help with osteoarthritis symptoms, though the expected benefit is limited and uncertain. The declaration identifies active SAMe, but that alone doesn't confirm its stability, enteric coating or how well it will be absorbed. Those preparation details matter when judging whether a retail serving will provide comparable symptom relief. SAMe shouldn't be expected to repair cartilage or prevent joint problems.

How this product is rated for Joint Health

Ingredient fit75

SAMe has a limited connection to osteoarthritis symptom relief.
Goal fit
SAMe has a limited connection to osteoarthritis symptom relief.
Dose adequacy
One serving supplies 400 mg active SAMe; the declared salt mass should not be added to this active amount.

Pathways15

SAMe relates to joint symptoms, but its proposed role should not be read as demonstrated cartilage repair.
Depth
SAMe relates to joint symptoms, but its proposed role should not be read as demonstrated cartilage repair.
Breadth
SAMe offers a narrow and uncertain symptom connection, without demonstrated structural joint benefits.

Evidence81

SAMe offers limited possible osteoarthritis symptom relief, without a reliable claim of medicine equivalence. Active SAMe quantity does not verify enteric coating, stability or equivalent absorption.
Evidence strength
SAMe offers limited possible osteoarthritis symptom relief, without a reliable claim of medicine equivalence.
Studied preparation
Active SAMe quantity does not verify enteric coating, stability or equivalent absorption.

Formulation logic100

The identified active ingredients do not require a missing partner. No particular ingredient conflict is identified.
Partner coverage
No additional required ingredient partner is missing for the identified active ingredients.
Conflicts
No particular ingredient conflict is identified in this combination.
Effective doses
One serving supplies 400 mg active SAMe; the declared salt mass should not be added to this active amount.
Study evidence
SAMe Supportive 9 studies
Detoxification
Detoxification
Impact
Highest effect
A Ingredient FitC- PathwaysA- EvidenceA+ Formulation Logic
SAMe · 400 mg

Whether SAMe helps remove toxins in everyday use is unclear. Its connection to liver disease does not transfer directly to routine cleansing in otherwise unselected adults. The 400 mg serving amount is known, but it doesn't show that this preparation will improve toxin clearance.

How this product is rated for Detoxification

Ingredient fit95

SAMe is present at a known amount, but routine toxin removal is uncertain.
Goal fit
SAMe has a liver-related connection, but routine toxin removal remains uncertain.
Dose adequacy
The serving supplies 400 mg of SAMe, matching the numerical comparison amount without demonstrating an effective routine detoxification dose.

Pathways59

The connection centers on methyl-group supply, without demonstrated routine toxin clearance.
Depth
Methyl-group supply is the main biological connection; this does not measure toxin clearance.
Breadth
The nutrients relate to several normal metabolic processes, without showing a broad cleansing effect.

Evidence86

Disease-specific liver effects cannot be assumed to improve routine toxin clearance.
Evidence strength
Disease-specific liver effects cannot be assumed to improve routine toxin clearance.
Studied preparation
Routine detoxification benefits remain unclear for this SAMe preparation.

Formulation logic100

The relevant ingredients work individually or have their listed partners, and no particular conflict is identified.
Partner coverage
SAMe does not require an added partner for its individual contribution.
Conflicts
No particular ingredient conflict is identified.
Effective doses
The serving supplies 400 mg of SAMe, matching the numerical comparison amount without demonstrating an effective routine detoxification dose.
Study evidence
SAMe Supportive 30 studies
Stress Relief
Stress Relief
Impact
High effect
B- Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe's connection to stress relief is indirect, through its role in mood and metabolism. Whether taking it helps you feel less stressed remains unconfirmed. Its presence alone therefore gives little guidance about the everyday relief you might notice.

How this product is rated for Stress Relief

Ingredient fit75

SAMe provides the relevant ingredient connection. The selected serving contains 400 mg SAMe, compared with the 800 mg daily quantity reference.
Goal fit
SAMe is the focused active ingredient relevant to stress.
Dose adequacy
The selected serving contains 400 mg SAMe, compared with the 800 mg daily quantity reference.

Pathways17

The relevant connection is to mood and the production of nerve-signalling chemicals. The connection is narrow and indirect, rather than a broad calming effect.
Depth
The relevant connection is to mood and the production of nerve-signalling chemicals.
Breadth
The connection is narrow and indirect, rather than a broad calming effect.

Evidence65

SAMe's mood and metabolic role gives only an indirect connection to stress relief.
Evidence strength
SAMe's mood and metabolic role gives only an indirect connection to stress relief.
Studied preparation
The declared SAMe preparation presents no separate preparation mismatch here.

Formulation logic100

No particular ingredient conflict or missing required partner is identified.
Partner coverage
The relevant ingredients do not require a missing partner for their individual roles.
Conflicts
No particular ingredient conflict is identified.
Effective doses
The 400 mg SAMe serving is below the 800 mg daily quantity reference.
Study evidence
SAMe Not classified

No linked studies yet.

Ingredients

IngredientAmount per servingScore
SAMe
400 mg 70
Gluten Free Adults 18–50 Vegan Dairy Free Vegetarian
Report overview
SAMe · 400 mg OverallScore70
B Active Ingredient Quality & BioavailabilityB- Dose, Safety & Label TransparencyD+ Value
The label lists 400 mg of SAMe per serving, but available details don't clarify its salt form or whether that amount is active SAMe or the salt complex. It doesn't say whether the tablets are blister-packed, and the cost per equivalent active amount is relatively high.
How this ingredient is rated

Active Ingredient Quality & Bioavailability77

The label names a specific SAMe salt, but its amount within the preparation isn't clear; blister packaging is also unspecified.
Stabilized Salt Form
The label names S-adenosyl-L-methionine disulfate tosylate, but its share of the SAMe preparation isn't clear.
Packaging Integrity
The available information doesn't say whether the tablets are sealed in protective blister packs.

Dose, Safety & Label Transparency72

The serving amount is stated, but the label doesn't clarify its active SAMe yield.
Active Dosage Strength
The serving lists 400 mg of SAMe.
Net SAMe Yield Transparency
The label gives an amount without distinguishing active SAMe from the salt complex.

Value50

The cost for an equivalent active amount is relatively high.
Price Per 400mg Active Dose
The cost per equivalent 400 mg amount is relatively high.
View ingredientView products
Loading alternative details
85 Performance

SAMe 400 mg

Lake Avenue Nutrition

A stabilized salt and enteric coating protect a full SAMe amount during storage and passage through the stomach. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Net active yield and moisture-resistant packaging remain unclear.

84 Performance

SAMe 400 mg

Life Extension

Enteric coating protects a full SAMe amount from stomach acid and supports purposeful delivery. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. The stabilized salt, net active yield, and moisture protection are not identified.

84 Performance

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt supplies a full SAMe amount in one tablet. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Enteric and sealed moisture protection are not stated, and net active yield remains unclear.

74 Budget

SAMe 200

Jarrow Formulas

A common starting SAMe amount provides a simple, low-cost option. It lowers routine cost versus the original. Neither a stabilized salt nor acid-resistant delivery is identified, so protected active yield is uncertain.

83 Budget

SAMe 200 mg

NOW

A stabilized disulfate tosylate salt provides a credible common starting amount at efficient routine value. It lowers routine cost versus the original. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

84 Budget

SAMe 400 mg

Nutricost

A stabilized salt provides a full SAMe amount with efficient dose value. It lowers routine cost versus the original. The two-capsule serving has no stated acid resistance, and moisture protection is unclear.

84 Value

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt provides a full SAMe amount with favorable dose value. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection and sealed moisture protection are not stated.

80 Value

SAMe 400 mg

Swanson

A stable disulfate tosylate form provides a full SAMe amount in one tablet. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

78 Value

SAMe 200 mg S-Adenosyl-Methionine

Life Extension

Enteric coating protects a common starting SAMe amount from stomach acid. Compared with the original, its delivery design and routine economics offer a useful value trade-off. The salt form, net active yield, and moisture protection are not identified.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis.
    Limveeraprajak N; Nakhawatchana S; Visukamol A; Siripakkaphant C; Suttajit S; Srisurapanont M · Progress in neuro-psychopharmacology & biological psychiatry · 2024
    Meta-analysis2,183 participants23 studies pooledMood Support forSAMe
  2. S-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: An updated systematic review and meta-analysis.
    Peng TR; Cheng HY; Wu TW · General hospital psychiatry · 2024
    Meta-analysis1,522 participants14 studies pooledMood Support forSAMe
  3. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
    Delle Chiaie R; Pancheri P; Scapicchio P · The American journal of clinical nutrition · 2002
    Randomized trial576 participantsMood Support forSAMe
  4. S-Adenosylmethionine for osteoarthritis of the knee or hip.
    Rutjes AW; Nüesch E; Reichenbach S; Jüni P · The Cochrane database of systematic reviews · 2010
    Meta-analysis656 participants4 studies pooledJoint Health forSAMe
  5. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
    Caruso I; Pietrogrande V · The American journal of medicine · 1988
    Clinical trial734 participantsJoint Health forSAMe
  6. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
    Najm WI; Reinsch S; Hoehler F; Tobis JS; Harvey PW · BMC musculoskeletal disorders · 2004
    Randomized trial61 participantsJoint Health forSAMe
  7. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
    Guo T; Chang L; Xiao Y; Liu Q · PloS one · 2015
    Meta-analysis705 participants11 studies pooledDetoxification forSAMe
  8. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
    Noureddin M; Sander-Struckmeier S; Mato JM · World journal of hepatology · 2020
    Systematic review9 studies pooledDetoxification forSAMe
  9. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial.
    Medici V; Virata MC; Peerson JM; Stabler SP; French SW; Gregory JF; Albanese A; Bowlus CL; Devaraj S; Panacek EA; Richards JR; Halsted CH · Alcoholism, clinical and experimental research · 2012
    Randomized trial37 participantsDetoxification forSAMe
  10. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
    Zhang L; Liu XH; Qi HB; Li Z; Fu XD; Chen L; Shao Y · European review for medical and pharmacological sciences · 2016
    Randomized trial120 participantsDetoxification forSAMe
  11. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
    Liu GY; Wang W; Jia WD; Xu GL; Ma JL; Ge YS; Yu JH; Sun QK; Meng FL · World journal of surgical oncology · 2014
    Non-randomized trial81 participantsDetoxification forSAMe
  12. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
    Mato JM; Cámara J; Fernández de Paz J; Caballería L; Coll S; Caballero A; García-Buey L; Beltrán J; Benita V; Caballería J; Solà R; Moreno-Otero R; Barrao F; Martín-Duce A; Correa JA; Parés A; Barrao E; García-Magaz I; Puerta JL; Moreno J; Boissard G; Ortiz P; Rodés J · Journal of hepatology · 1999
    Randomized trial123 participantsDetoxification forSAMe
  13. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
    Glorioso S; Todesco S; Mazzi A; Marcolongo R; Giordano M; Colombo B; Cherie-Ligniere G; Mattara L; Leardini G; Passeri M · International journal of clinical pharmacology research · 1985
    Randomized trial150 participantsJoint Health forSAMe
  14. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
    König B · The American journal of medicine · 1988
    Single-arm trial108 participantsJoint Health forSAMe
  15. Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
    Hosea Blewett HJ · Critical reviews in food science and nutrition · 2008
    Narrative reviewJoint Health forSAMe
  16. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
    Pancheri P; Scapicchio P; Chiaie RD · The international journal of neuropsychopharmacology · 2004
    Randomized trial293 participantsMood Support forSAMe
  17. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
    Di Pierro F; Settembre R · International journal of general medicine · 2015
    Randomized trial64 participantsMood Support forSAMe
  18. S-adenosylmethionine blood levels in major depression: changes with drug treatment.
    Bell KM; Potkin SG; Carreon D; Plon L · Acta neurologica Scandinavica. Supplementum · 1994
    Randomized trial26 participantsMood Support forSAMe
  19. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.
    Sarris J; Murphy J; Mischoulon D; Papakostas GI; Fava M; Berk M; Ng CH · The American journal of psychiatry · 2017
    Meta-analysisMood Support forSAMe